Human epidermal growth
factor receptor 2 (HER2) overexpression occurs in up to 30% of breast cancers
and is a marker of aggressive disease. While HER2-targeted therapies have
improved outcomes in these tumors, resistance to these agents develops in a
large proportion of patients. Determining molecular mechanisms underlying
resistance might help improve outcomes for patients with HER2-positive disease
by allowing development of strategies to overcome resistance. Activation of
signaling pathways involving the phosphoinositide 3-kinase/protein kinase
B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway might contribute to the
development of resistance to HER2-targeted therapies.
http://dx.doi.org/10.1016/j.breast.2015.06.002
http://dx.doi.org/10.1016/j.breast.2015.06.002
